Shopping Cart (0)
My Account

 Shopping Cart
Conferences | Training Courses | Market Reports | Managed Events | Past Conferences | Update Me
SELECTBIO Conferences Antibody and Peptide Therapeutics
Conferences  \  BioProcessing, Biologics & Biotherapeutics Congress  \  Antibody and Peptide Therapeutics  \  Agenda  \  Thomas Schirrmann
RegisterLogin

Thomas Schirrmann's Biography


Thomas Schirrmann, Research Group Leader, Technische Universitaet Braunschweig

Sorry, There is currently no biography for this presenter.

Thomas Schirrmann Image

Antibodies and Antibody RNase Fusion Proteins Targeting CD30+ Lymphoma

Wednesday, 20 July 2011 at 11:15

Add to Calendar ▼2011-07-20 11:15:002011-07-20 12:15:00Europe/LondonAntibodies and Antibody RNase Fusion Proteins Targeting CD30+ LymphomaSELECTBIOenquiries@selectbiosciences.com

CD30 specific recombinant human antibodies and immunoRNases are produced in high levels using mammalian cell lines. Antibodies as well as immunoRNases mediate inhibitory effects on Hodgkin lymphoma cell lines but immunoRNases show higher efficacy.

Add to Calendar ▼2011-07-20 00:00:002011-07-21 00:00:00Europe/LondonAntibody and Peptide TherapeuticsSELECTBIOenquiries@selectbiosciences.com


Corporate Sponsors